Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK announces new partnership with academia

GSK announces new partnership with academia

24th July 2008

GlaxoSmithKline (GSK) has announced a new partnership with academia for the development of new medicines of value.

Under the terms of the deal, the University of Cambridge will dedicate a team of academic experts in metabolic disorders and neuroscience to the development of a novel centrally-acting compound with therapeutic potential for addictive disorders and obesity.

The university will bear some financial risk for the “academic incubator” programme, which will be compensated for if the programme is successful.

It will also provide its expertise, while GSK will provide operational support, access to in-house clinical research and imaging facilities and preclinical data on the compound.

Academic scientists will be given freedom to publish results arising from their work on projects.

Patrick Vallance, senior vice-president of drug discovery at GSK, said: “This puts academia/industry relationships on a new footing and allows academics, who are leaders in their fields, the opportunity to become directly involved in developing medicines for patients.”

He added that academic incubator initiative will also give academics the opportunity to take the programme in exciting new directions.

Earlier this week, GSK reached a settlement with Biota Holdings in their litigation regarding the commercialisation of Relenza (zanamivir).

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.